Parabilis Debuts With $670 Million Nasdaq IPO as Biotech Window Reopens for De-Risked Pipelines
Updated
Updated · BioSpace · Jun 11
Parabilis Debuts With $670 Million Nasdaq IPO as Biotech Window Reopens for De-Risked Pipelines
3 articles · Updated · BioSpace · Jun 11
Summary
Parabilis set a new biotech IPO record with a $670 million Nasdaq debut, overtaking Kailera’s $625 million raise and closing its first session up 58% at $31.60.
A $75 million concurrent Regeneron placement could lift the total to about $845 million, while pricing 25% above the midpoint signaled an oversubscribed order book and strong post-listing demand.
Parabilis’ appeal rested on a more validated setup than the 2021 boom: lead cancer asset zolucatetide had a strong 2025, a $305 million crossover round in January, and FDA fast-track and orphan-drug designations in March.
Analysts said the surge also reflects spillover from the AI IPO frenzy, inflation-driven larger raises, and a backlog of private biotechs, but they argued 2026 deals are still being priced on advanced clinical programs rather than preclinical hype.
That distinction matters for what comes next: Kardigan is already pursuing a smaller $373.3 million IPO, and investors are watching whether Parabilis can hold its gains better than Kailera, whose shares are down 24% since April 17.